
News|Articles|October 20, 2026 (Updated: October 21, 2026)
(FAQ) Inflammatory Eye Disease Week: What clinicians should know
Author(s)Sheryl Stevenson
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Advertisement
Advertisement
Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting
Related to this article

Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.

Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Advertisement
Advertisement



